GS Meneilly, CHS McIntosh, RA Pederson, JF … - Diabetes Care, 2001 - Am Diabetes Assoc An important cause of elevated glucose levels in elderly patients with diabetes
is an alteration in non–insulin-mediated glucose uptake (NIMGU). Glucagon-like
peptide 1 (GLP-1) is an intestinal insulinotropic hormone. It has been ... Cited by 61 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org [PDF] SA Hinke, CHS McIntosh, T Hoffmann, K … - Diabetes Care, 2002 - Am Diabetes Assoc The provision of diabetes care has shifted from the specialist to the generalist
in primary care practice. Evidence suggests utilization of nonphy- sician
providers in conjunction with phy- sician-directed protocols improves ... Cited by 28 - Related articles - BL Direct - All 5 versions
[CITATION] Single dose treatment of diabetic patients by the DPIV inhibitor P32/98
HU Demuth, T Hoffmann, K Glund, CHS … - EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY …, 2000 - Johann Ambrosius Barth; 1999 Cited by 33 - Related articles - BL Direct
- ►nih.gov [PDF] DA D'alessio, SE Kahn, CR Leusner, JW … - Journal of Clinical Investigation, 1994 - pubmedcentral.nih.gov Glucagon-like peptide1 [7-36 amidel (GLP-1) has been shown to enhance insulin
secretion in healthy and type II diabetic hu- mans, and to increase glucose
disposal in type I diabetic pa- tients. To further define its action on ... Cited by 172 - Related articles - BL Direct - All 6 versions
A Vella, P Shah, A Reed, A Adkins, R Basu, R … - Diabetologia, 2002 - Springer Aims/hypothesis. The aim of this study was to determine whether rapid conversion
to inactive and potentially an- tagonistic peptides could alter the response to
GLP-1. Methods. We evaluated the ability of exendin-4, a GLP-1 analogue ... Cited by 41 - Related articles - BL Direct - All 4 versions
- ►endojournals.org JM Egan, GS Meneilly, JF Habener, D Elahi - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc The insulinotropic hormone, glucagon-like peptide-1 (GLP-1), is being examined
as a potential new agent for treatment in type 2 diabetic patients. Whereas the
insulinotropic properties of this peptide are well established, another ... Cited by 60 - Related articles - BL Direct - All 8 versions
- ►endojournals.org AS Ryan, JM Egan, JF Habener, D Elahi - Journal of Clinical Endocrinology & Metabolism, 1998 - Endocrine Soc Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that
augments insulin secretion in response to meals and lowers blood glucose levels
in both type 1 and type 2 diabetic subjects. It has been proposed that a ... Cited by 55 - Related articles - BL Direct - All 5 versions
L Ørskov, JJ Holst, J Møller, C Ørskov, N … - Diabetologia, 1996 - Springer Summary Previous studies have suggested that gluca- gon-like peptide-1 (GLP-1)
(7-36 amide) may have the direct effect of increasing insulin sensitivity in
healthy man. To evaluate this hypothesis we infused GLP-1 in seven lean ... Cited by 72 - Related articles - BL Direct - All 4 versions
GS Meneilly, CHS McIntosh, RA Pederson, JF … - Journals of Gerontology Series A: Biological and …, 2001 - Geron Soc America Results. Glucose values were similar between the control and GLP-1 infusion
studies. 120- to 180-minute insulin values appeared to be higher during the
GLP-1 infusion study (control, 795 ± 63 pmol/l; GLP-1, 1140 ± 275 pmol/l; ... Cited by 22 - Related articles - All 2 versions
- ►diabetesjournals.org R Lupi, S Del Guerra, V Fierabracci, L Marselli … - Diabetes, 2002 - Am Diabetes Assoc Human pancreatic islets from eight donors were incubated for 48 h in the
presence of 2.0 mmol/l free fatty acid (FFA) (oleate to palmitate, 2 to 1).
Insulin secretion was then assessed in response to glucose (16.7 mmol/l), ... Cited by 80 - Related articles - BL Direct - All 5 versions
